Plain-Language Summary
Plain-language reading of the public trial registries.
In short
- Very little human research on Pemvidutide has been registered.
- 15 registered studies in total.
- None are currently enrolling — this research has already happened.
What kind of research
- 15 studies actually gave the peptide to volunteers and measured what happened. This is the kind of study that can show whether something works.
- About 1,315 people took part in those.
How far along it is
- None have reached phase 3 — the large, late-stage trials where a drug has to prove itself before regulators will approve it.
- 4 have published results in the medical literature that anyone can read.
- The research spans 3 countries.
A registered trial is a plan, not a result. Registration means a study was declared in advance; it says nothing about whether the peptide worked, and a trial can be registered and then abandoned.
Filter
Showing 15 of 15 trials for Pemvidutide.
RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)
Altimmune, Inc.
Alcohol-associated Liver Disease
RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight
Altimmune, Inc.
Alcohol Use Disorder (AUD)
IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)
Altimmune, Inc.
Non-Alcoholic Steatohepatitis (NASH)
Efficacy and Safety of ALT-801 in the Treatment of Obesity
Altimmune, Inc.
Obesity/Overweight
Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)
Altimmune, Inc.
Non-Alcoholic Fatty Liver Disease
ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)
Altimmune, Inc.
Type 2 Diabetes
ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)
Altimmune, Inc.
Non-Alcoholic Fatty Liver Disease
Pemvidutide (ALT-801) DDI Study in Healthy Volunteers
Altimmune, Inc.
NASH - Nonalcoholic Steatohepatitis
ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability
Altimmune, Inc.
Obesity · Nonalcoholic Steatohepatitis
QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma
Altor BioScience
Relapsed or Refractory Multiple Myeloma
A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer
Altor BioScience
Non-muscle Invasive Bladder Cancer
ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia
Altor BioScience
Acute Myeloid Leukemia
A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer
Altor BioScience
Transitional Cell Carcinoma of Bladder · Urethra Cancer · Ureter Cancer · Malignant Tumor of Renal Pelvis
QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Altor BioScience
Metastatic Melanoma
Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies
Altor BioScience
Progressive Metastatic Malignancies
Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered in more than one registry is counted once. A study is listed when Pemvidutide is named as an intervention. A registered trial is a plan, not a result — registration says nothing about whether the peptide worked.